La cadena de opciones muestra datos clave de las opciones de acciones de Innate Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Innate Pharma..

Innate Pharma (NASDAQ:IPHA) Bolsa, Cadena de Opciones

INNATE PHARMA SA-SPONS ADR

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

Press Releases

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

Number of Shares and Voting Rights of Innate Pharma as of August 1, 2025

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

Innate Pharma Reports First Half 2025 Business Update and Financial Results

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

PARIS:IPH

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Elicio Therapeutics

Fate Therapeutics

Forte Biosciences

Genfit

Heron Therapeutics

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tenaya Therapeutics

Vor Biopharma

HC Wainwright & Co.

BTIG

Leerink Partners

SVB Leerink

Comments

Innate Pharma

Innate Pharma (IPHA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL